NA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

North America psychedelic drugs market is projected to register a substantial CAGR of 13.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029

Market Segmentation: 

North America Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin & Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder & Others), Route of Administration (Oral, Inhalation & Injectable), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy & Online Pharmacy), Country (U.S., Canada, Mexico). Market Trends and Forecast to 2029

Some of the major factors contributing to the growth of the North America psychedelic drugs are:

• Rising awareness towards mental health

• Increasing prevalence of depression and mental disorders

Market Players:

The key market players for North America psychedelic drugs market are listed below:

• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• COMPASS
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Jazz Pharmaceuticals, Inc.
• PharmaTher Inc.
• Avadel
• NeuroRx, Inc.
• usonainstitute.org
• Mind Medicine, Inc.
• Cybin Corp.
• DemeRx
• GABA Therapeutics, Inc.
• EmpathBio